<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789408</url>
  </required_header>
  <id_info>
    <org_study_id>KT-US-486-0201</org_study_id>
    <secondary_id>2020-000962-40</secondary_id>
    <nct_id>NCT04789408</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the feasibility, safety, maximum tolerated&#xD;
      dose (MTD), and optimal dose of KITE-222 in the treatment of participants with&#xD;
      relapsed/refractory (r/r) acute myeloid leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">January 2039</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>First infusion date of KITE-222 up to 28 days</time_frame>
    <description>DLTs are defined as KITE-222-related events with an onset within the first 28 days after the KITE-222 infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Clinically Significant Changes in Laboratory Parameters</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Neutrophil Recovery</measure>
    <time_frame>First infusion date of KITE-222 up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Platelet Recovery</measure>
    <time_frame>First infusion date of KITE-222 up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Complete Remission (CCR) Rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>CCR rate is defined as the proportion of participants who achieve a complete remission (CR) plus the proportion of participants who achieve a CR without measurable residual disease (CRMRD-) plus the proportion of participants who achieve a CR with incomplete hematologic recovery (CRi) per the European Leukemia Net (ELN) 2017 classification, as determined by the study investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Remission Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR is defined as CR + CRMRD- + CRi + morphologic leukemia-free state (MLFS) + partial remission (PR) per the ELN 2017 classification, as determined by the study investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival (RFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>For participants who experience CR, CRMRD-, or CRi, RFS is defined as the time between their first CR/CRMRD-/CRi to relapse or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allogeneic Stem Cell Transplant (allo-SCT) Rate</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>First infusion date of KITE-222 up to 24 months</time_frame>
    <description>EFS is defined as the time from the KITE-222 infusion date to the earliest date of disease relapse, progressive disease, refractory disease, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>First infusion date of KITE-222 up to 15 years</time_frame>
    <description>OS is defined as the time from KITE-222 infusion to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Day All-cause Mortality Rate</measure>
    <time_frame>First infusion date of KITE-222 up to 30 days</time_frame>
    <description>The mortality rate is calculated by number of deaths, regardless of cause, within 30 days from the KITE-222 infusion date divided by the total number of participants included in the safety analysis set. The safety analysis set consists of all participants treated with any dose of KITE-222.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>60 Day All-cause Mortality Rate</measure>
    <time_frame>First infusion date of KITE-222 up to 60 days</time_frame>
    <description>The mortality rate is calculated by number of deaths, regardless of cause, within 60 days from the KITE-222 infusion date divided by the total number of participants included in the safety analysis set. The safety analysis set consists of all participants treated with any dose of KITE-222.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Peak Plasma Concentration of KITE-222 CAR T Cells in Participants With Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Treated with KITE-222</measure>
    <time_frame>Enrollment (before leukapheresis) and D0 (predose), D3,7,10,14 &amp;21, W4, PTFU (W6, M2,3,6,9,12,15,18 &amp;24 and at relapse for participants without allo-SCT or within 1 W before CC, D-1 of allo-SCT, M1,3,6,12 &amp;24 and at relapse for participants with allo-SCT</time_frame>
    <description>PK will be assessed at enrollment (before start of leukapheresis) and Day 0 (predose) and on Days 3, 7, 10, 14 &amp; 21, Week 4, post-treatment follow-up (Week 6, Months 2, 3, 6, 9, 12, 15, 18, &amp; 24 and at relapse for participants without allo-SCT or within 1 week before conditioning chemotherapy and Day -1 of allo-SCT, Months 1, 3, 6,12 &amp; 24 and at relapse for participants with allo-SCT).&#xD;
CC=conditioning chemotherapy&#xD;
D=Day(s)&#xD;
M=Month&#xD;
PTFU= post-treatment follow-up&#xD;
W=Week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUC of KITE-222 CAR T Cells in Participants With r/r AML Treated with KITE-222</measure>
    <time_frame>Enrollment (before leukapheresis) and D0 (predose), D3,7,10,14 &amp;21, W4, PTFU (W6, M2,3,6,9,12,15,18 &amp;24 and at relapse for participants without allo-SCT or within 1 W before CC, D-1 of allo-SCT, M1,3,6,12 &amp;24 and at relapse for participants with allo-SCT</time_frame>
    <description>AUC is defined as the area under the concentration versus time curve. PK will be assessed at enrollment (before start of leukapheresis) and Day 0 (predose) and on Days 3, 7, 10, 14 &amp; 21, Week 4, post-treatment follow-up (Week 6, Months 2, 3, 6, 9, 12, 15, 18, &amp; 24 and at relapse for participants without allo-SCT or within 1 week before conditioning chemotherapy and Day -1 of allo-SCT, Months 1, 3, 6,12 &amp; 24 and at relapse for participants with allo-SCT).&#xD;
CC=conditioning chemotherapy&#xD;
D=Day(s)&#xD;
M=Month&#xD;
PTFU= post-treatment follow-up&#xD;
W=Week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Peak Plasma of Key Analytes (Pro-inflammatory and Immune-modulating Cytokines, Chemokines, and Effector Molecules) in Participants With r/r AML Treated with KITE-222</measure>
    <time_frame>Enrollment (before leukapheresis) and Days -5 &amp; 0 (predose) and Days 1-13 every other day,14,21, Week 4, post-treatment follow-up (Month 2 and at relapse for participants without allo-SCT or at relapse for participants with allo-SCT)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Parameter: AUC of Key Analytes (Pro-inflammatory and Immune-modulating Cytokines, Chemokines, and Effector Molecules) in Participants With r/r AML Treated with KITE-222</measure>
    <time_frame>Enrollment (before leukapheresis) and Days -5 &amp; 0 (predose) and Days 1-13 every other day,14,21, Week 4, post-treatment follow-up (Month 2 and at relapse for participants without allo-SCT or at relapse for participants with allo-SCT)</time_frame>
    <description>AUC is defined as the area under the concentration versus time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Develop Anti-KITE-222 CAR Antibodies</measure>
    <time_frame>Enrollment (before leukapheresis),Week 4, post-treatment follow-up (Month 3 and at relapse for participants without allo-SCT or within 1 week before conditioning chemotherapy and at relapse for participants with allo-SCT)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>KITE-222</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-222 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-222 to determine the maximum tolerated dose (MTD) of KITE-222.&#xD;
Dose Expansion: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose (at the MTD determined) of KITE-222.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>KITE-222</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>KITE-222</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KITE-222</intervention_name>
    <description>A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously</description>
    <arm_group_label>KITE-222</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML)&#xD;
&#xD;
          -  Morphological disease in the bone marrow and/or peripheral blood within 28 days before&#xD;
             enrollment&#xD;
&#xD;
          -  Prior exposure to the relevant agent class for individuals with AML characterized by a&#xD;
             mutation targeted by an approved therapy&#xD;
&#xD;
          -  Institutional criteria for allo-SCT fitness must be met: individuals must have an&#xD;
             identified stem-cell donor readily available for potential allo-SCT after therapy with&#xD;
             KITE-222&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Adequate hematologic status, defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000/µL unless, in the opinion of the&#xD;
                  investigator, cytopenia is due to underlying leukemia&#xD;
&#xD;
               -  Platelet count ≥ 50,000/µL unless, in the opinion of the investigator,&#xD;
                  thrombocytopenia is due to underlying leukemia&#xD;
&#xD;
               -  Absolute lymphocyte count (ALC) ≥ 100/µL&#xD;
&#xD;
          -  Adequate renal, hepatic, pulmonary and cardiac function defined as:&#xD;
&#xD;
               -  Creatinine clearance (as estimated by the Cockcroft Gault formula) ≥ 60 mL/min&#xD;
&#xD;
               -  Serum alanine aminotransferase/aspartate aminotransferase ≤ 2.5 x upper limit of&#xD;
                  normal&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 mg/dL, except in individuals with Gilbert's syndrome&#xD;
&#xD;
               -  Cardiac ejection fraction ≥ 50%, no clinically significant pericardial effusion&#xD;
                  as determined by an echocardiogram (ECHO), and no clinically significant&#xD;
                  electrocardiogram (ECG) findings&#xD;
&#xD;
               -  Baseline oxygen saturation &gt; 92% on room air and no clinically significant&#xD;
                  pleural effusion as determined by chest imaging&#xD;
&#xD;
          -  Contraception: males and females of childbearing potential must agree to use an&#xD;
             effective method of contraception&#xD;
&#xD;
          -  Pregnancy testing: females of childbearing potential must have a negative serum or&#xD;
             urine pregnancy test&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of acute promyelocytic leukemia&#xD;
&#xD;
          -  Auto-SCT within the 6 weeks before enrollment&#xD;
&#xD;
          -  Donor Lymphocyte Infusions (DLI) within 28 days prior to enrollment&#xD;
&#xD;
          -  Any drug used for graft-versus-host-disease (GVHD) within 4 weeks prior to enrollment&#xD;
&#xD;
          -  Acute GVHD grade II-IV by Mount Sinai Acute GVHD International Consortium criteria&#xD;
&#xD;
          -  Active central nervous system (CNS) disease involvement&#xD;
&#xD;
          -  Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg,&#xD;
             leukostasis or tumor lysis syndrome (TLS)) or the possible requirement for urgent&#xD;
             therapy due to ongoing or impending oncologic emergency (eg, spinal cord compression,&#xD;
             bowel obstruction, leukostasis, or TLS) at the time of enrollment or KITE-222 infusion&#xD;
&#xD;
          -  History of C-type lectin-like molecule-1 (CLL-1)-directed therapy or genetically&#xD;
             modified T-cell therapy&#xD;
&#xD;
          -  History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg,&#xD;
             cervix, bladder, or breast) unless disease free for at least 3 years after the last&#xD;
             definitive therapy&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to aminoglycosides&#xD;
&#xD;
          -  History of concomitant genetic syndrome associated with bone marrow failure&#xD;
&#xD;
          -  Individuals with a genetic syndrome that increases the risk of allo-SCT, including&#xD;
             Down syndrome (trisomy 21)&#xD;
&#xD;
          -  History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,&#xD;
             New York Heart Association Class II or greater congestive heart failure, atrial&#xD;
             fibrillation, or other clinically significant cardiac disease within 12 months before&#xD;
             enrollment&#xD;
&#xD;
          -  Individuals with cardiac atrial or ventricular leukemia involvement&#xD;
&#xD;
          -  History of symptomatic deep vein thrombosis (DVT) or a pulmonary embolism within 6&#xD;
             months of enrollment. History of upper extremity line related DVT within the 3 months&#xD;
             of conditioning chemotherapy.&#xD;
&#xD;
          -  Primary immunodeficiency disorders&#xD;
&#xD;
          -  History of a human immunodeficiency virus (HIV) infection or acute or chronic active&#xD;
             hepatitis B or C infection&#xD;
&#xD;
          -  History of an autoimmune disease resulting in end-organ injury or requiring systemic&#xD;
             immunosuppression or systemic disease modifying agents within the last 2 years&#xD;
&#xD;
          -  History or presence of a CNS disorder&#xD;
&#xD;
          -  Presence or suspicion of a fungal, bacterial, viral, or other infection that is&#xD;
             uncontrolled or requiring antimicrobials for management&#xD;
&#xD;
          -  Live vaccine received within the ≤ 4 weeks before enrollment, or anticipation of the&#xD;
             need for a live vaccination during the course of the study&#xD;
&#xD;
          -  Inability to tolerate prophylactic antifungal and antibacterial therapy&#xD;
&#xD;
          -  Presence of any indwelling line or drain&#xD;
&#xD;
          -  Ongoing Grade 2 or higher toxicities from previous therapies, excluding hematologic&#xD;
             toxicities&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant or breastfeeding&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kite Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>844-454-5483 (1-844-454-KITE)</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gileadclinicaltrials.com/study/?id=KT-US-486-0201</url>
    <description>Gilead Clinical Trials Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

